Survival Gains from First‐Line Systemic Therapy in Metastatic Non‐Small Cell Lung Cancer in the U.S., 1990–2015: Progress and Opportunities

BACKGROUND. Approximately 190,000 Americans are diagnosed with non‐small cell lung cancer (NSCLC) annually, and about half have metastatic (Stage IV) disease. These patients have historically had poor survival prognosis, but several new therapies introduced since 2000 provide options for improved ou...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Roth, Joshua A., Goulart, Bernardo H. L., Ravelo, Arliene, Kolkey, Holli, Ramsey, Scott D.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2017
Témata:
Health Outcomes and Economic of Cancer Care
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344635/
https://ncbi.nlm.nih.gov/pubmed/28242792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0253
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky